Syndax Pharmaceuticals (SNDX) H.C. Wainwright 27th Annual Global Investment Conference summary

Business highlights and financial performance

• Achieved $100 million in net sales in the first six months, exceeding expectations and supporting a path to profitability.

• Maintains over $500 million in cash with a stabilizing expense base, enabling investment in multi-billion dollar franchises.

• Both products, Revuforj and Niktimvo, are contributing significantly to cash flow and profitability.

• Early launches of both products have been highly successful, with strong momentum projected into 2025 and beyond.

Revuforj: Market position and growth

• First and only FDA-approved menin inhibitor for relapsed/refractory acute leukemia with KMT2A translocation, approved in late 2024.

• Achieved 43% quarter-over-quarter sales growth, with $28.6 million in Q2 and over 1,300 prescriptions since launch.

• Penetration expected to reach 50% of the 2,000-patient incidence population by year-end.

• Anticipates first approval for relapsed/refractory NPM1 in October, expanding the addressable market to 6,500 patients.

• Robust development strategy targets both relapsed/refractory and frontline disease, aiming for a $5 billion total addressable market.

Niktimvo: Launch and market expansion

• First and only FDA-approved CSF1R antibody for chronic GVHD, launched in early 2024.

• Achieved profitability in the first full quarter, with $36.2 million in net sales and $9.4 million in collaboration revenue.

• Over 700 patients treated and more than 4,000 infusions administered, with 80%-90% patient persistence.

• Targeting a $2 billion market in third line plus, with plans to expand into earlier lines and IPF, potentially unlocking a $5 billion market.

• Co-commercialization with Incyte provides commercial synergies and broad market reach.